Search

目的 明确真实世界内蒙古包头地区40岁及以上人群抗血小板聚集类药物的使用情况，以及不同人群服药率的影响因素。 方法 采用以居委会、村委会为单位的多级、整群、随机抽样方法，在2021年6月—2022年9月抽取包头地区40岁及以上常住居民。采用调查问卷形式收集研究对象的一般资料、既往病史及抗血小板聚集类药物使用情况。按照是否有心脑血管疾病（cardio cerebrovascular diseases，CVD）以及是否存在CVD危险因素将研究对象分为3组：CVD组（既往患CVD人群）、CVD危险因素组（无CVD病史，有以下1个或多个CVD危险因素：高血压、糖尿病、高血脂、吸烟史、饮酒史、肥胖）、健康对照组（无CVD病史，无CVD危险因素）。比较3组间一般资料的差异。根据是否服用抗血小板聚集类药物，将CVD组和CVD危险因素组的研究对象分别分为服药组和未服药组，采用单因素和多因素分析调查两组中影响服药的相关因素。 结果 ①研究共纳入2100例有效调查对象，其中CVD组298例（14.2%）、CVD危险因素组1040例（49.5%）、健康对照组762例（36.3%）。3组人群中抗血小板聚集类药物应用率分别为51.68%（154例）、33.46%（348例）和6.69%（51例），组间差异有统计学意义（P＜0.001）。②多因素分析显示，CVD组中较高学历（以小学及以下学历为基线，高中OR 2.429，95%CI 1.277～4.619，P=0.007、本科及以上学历OR 8.500，95%CI 1.015～12.165，P=0.048）以及合并糖尿病（OR 2.820，95%CI 1.377～5.777，P=0.005）的患者更倾向于应用抗血小板聚集类药物；CVD危险因素组中抗血小板聚集类药物应用率受个人经济收入（以＜1.0万/年为基线，＞5.0万/年 OR 18.547，95%CI 8.948～38.444，P＜0.001）、学历（以小学及以下学历为基线，本科及以上学历OR 5.512，95%CI 1.736～17.495，P=0.004）、吸烟史（OR 0.712，95%CI 0.541～0.936，P=0.015）、BMI（与低BMI患者相比，BMI正常OR 5.640，95%CI 1.172～27.144，P=0.031）；肥胖 （OR 8.440，95%CI 1.684～42.293，P=0.009）、患高血压（OR 246.029，95%CI 112.44～538.337， P＜0.001）、患糖尿病（OR 117.689，95%CI 51.041～271.367，P＜0.001）等因素的独立影响。③CVD组和CVD危险因素组的服药原因中医师处方占比最高，分别为83.12%和79.60%；健康对照组服药原因从高到低依次为自觉应该服用（47.06%）、亲友介绍（29.41%）、广告媒体宣传（13.73%）和医师处方（9.80%）。 结论 内蒙古包头地区40岁及以上人群中使用抗血小板聚集类药物进行CVD一级、二级预防的情况不理想，不同人群服药影响因素各不相同，且存在健康人群不规范和错误用药情况。 Abstract: Objective To clarify the use of antiplatelet aggregating drugs in people aged 40 years and above in Baotou area of Inner Mongolia in the real world, and the factors influencing the rate of taking drugs in different populations. Methods A multilevel, whole-group, random sampling method with neighborhood and village committees was used to draw permanent residents aged 40 years and above in Baotou area from June 2021 to September 2022. A questionnaire was used to collect general information, past medical history and the use of anti-platelet aggregating drugs from the study population. The subjects were divided into three groups according to the presence or absence of cardio cerebrovascular diseases (CVD) and the presence of CVD risk factors: CVD group (with previous CVD), CVD risk factor group (no history of CVD, with one or more of the following CVD risk factors: hypertension, diabetes mellitus, hyperlipidemia, history of smoking, history of alcohol consumption, obesity), the healthy control group (no history of CVD, no risk factors for CVD). The differences in general information between the 3 groups were compared. The subjects in the CVD group and the CVD risk factor group were divided into the medication group and the non-medication group according to whether they were taking antiplatelet aggregation drugs or not, and the relevant factors affecting medication taking in the two groups were investigated using univariate and multifactorial analyses. Results ①A total of 2100 validated subjects were included in the study, including 298 cases (14.2%) in the CVD group, 1040 cases (49.5%) in the CVD risk factor group, and 762 cases (36.3%) in the healthy control group.The rates of taking antiplatelet aggregation drugs in the three groups were 51.68% (154 cases), 33.46% (348 cases), and 6.69% (51 cases), respectively, with statistically significant differences between groups (P50 000/year, OR 18.547, 95%CI 8.948-38.444, P

OBJECTIVE: To explore the clinical characteristics and risk factors of patients with hemorrhage of digestive tract caused by antiplatelet drugs. METHODS: Retrospective study method was used, a total of 180 patients with cardiovascular and cerebrovascular diseases who were treated with antiplatelet drugs [ aspirin and ( or ) clopidogrel] for hemorrhage of digestive tract from 2021 to 2022 in the gastroenterology department of the hospital were extracted as the observation group, and 180 patients with cardiovascular and cerebrovascular diseases who were treated with antiplatelet drugs [ aspirin and ( or) clopidogrel] during the same period without hemorrhage of digestive tract were extracted as the control group. The clinical characteristics of hemorrhage of digestive tract in the observation group were analyzed. General demographic data, biochemical indexes and the use of antiplatelet drugs were collected. Logistic regression analysis was used to explore the influencing factors of hemorrhage of digestive tract caused by antiplatelet drugs, and the receiver operator characteristic curve was established to evaluate the accuracy of the influencing factors in predicting hemorrhage of digestive tract. RESULTS: Of the 180 patients with hemorrhage of digestive tract, the highest proportion of the first clinical symptoms was black stool ( 72 cases, 40. 0%), and the lowest proportion was only stool occult blood test positive (17 cases, 9. 4%). The proportion of patients with mild bleeding was the highest (87 cases, 48. 3%), followed by moderate bleeding (74 cases, 41. 1%). The proportion of patients with moderate anemia took the lead (97 cases, 53. 9%), while patients with severe anemia were the lowest (35 cases, 19. 4%). The main endoscopic lesions were erosive gastritis (110 cases, 61. 1%), followed by peptic ulcer (38 cases, 21. 1%). Logistic regression analysis showed that age, history of hypertension, history of digestive tract diseases, Helicobacter pylori ( Hp ) infection, Hp infection complicated with mucosal atrophy, abnormal hemoglobin (Hb), abnormal serum creatinine (Cr), type of drug use, course of treatment, and combination of PPI were the influencing factors for hemorrhage of digestive tract caused by antiplatelet drugs (P<0. 05). The obtained dependent variables were combined to predict the probability of hemorrhage of digestive tract caused by antiplatelet drugs, with a predictive sensitivity of 0. 606, a specificity of 0. 900, a Yoden index of 0. 506, a threshold of 0. 616, and an area under the curve of 0. 809. CONCLUSIONS: The first symptom of hemorrhage of digestive tract caused by antiplatelet drugs is mostly black stool. Mild to moderate bleeding and moderate anemia can be observed. Age, history of hypertension, history of digestive tract diseases, Hp infection, Hp infection complicated with mucosal atrophy, abnormal Hb, abnormal Cr, type of drug use, course of treatment, and combination of PPI are related factors that affect hemorrhage of digestive tract caused by antiplatelet drugs. Clinical intervention should be actively targeted at bleeding factors, and joint evaluation of factors affecting hemorrhage of digestive tract caused by antiplatelet drugs has certain predictive value. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To explore the clinical characteristics and risk factors of patients with hemorrhage of digestive tract caused by antiplatelet drugs. METHODS: Retrospective study method was used, a total of 180 patients with cardiovascular and cerebrovascular diseases who were treated with antiplatelet drugs [ aspirin and ( or ) clopidogrel] for hemorrhage of digestive tract from 2021 to 2022 in the gastroenterology department of the hospital were extracted as the observation group, and 180 patients with cardiovascular and cerebrovascular diseases who were treated with antiplatelet drugs [ aspirin and ( or) clopidogrel] during the same period without hemorrhage of digestive tract were extracted as the control group. The clinical characteristics of hemorrhage of digestive tract in the observation group were analyzed. General demographic data, biochemical indexes and the use of antiplatelet drugs were collected. Logistic regression analysis was used to explore the influencing factors of hemorrhage of digestive tract caused by antiplatelet drugs, and the receiver operator characteristic curve was established to evaluate the accuracy of the influencing factors in predicting hemorrhage of digestive tract. RESULTS: Of the 180 patients with hemorrhage of digestive tract, the highest proportion of the first clinical symptoms was black stool ( 72 cases, 40. 0%), and the lowest proportion was only stool occult blood test positive (17 cases, 9. 4%). The proportion of patients with mild bleeding was the highest (87 cases, 48. 3%), followed by moderate bleeding (74 cases, 41. 1%). The proportion of patients with moderate anemia took the lead (97 cases, 53. 9%), while patients with severe anemia were the lowest (35 cases, 19. 4%). The main endoscopic lesions were erosive gastritis (110 cases, 61. 1%), followed by peptic ulcer (38 cases, 21. 1%). Logistic regression analysis showed that age, history of hypertension, history of digestive tract diseases, Helicobacter pylori ( Hp ) infection, Hp infection complicated with mucosal atrophy, abnormal hemoglobin (Hb), abnormal serum creatinine (Cr), type of drug use, course of treatment, and combination of PPI were the influencing factors for hemorrhage of digestive tract caused by antiplatelet drugs (P<0. 05). The obtained dependent variables were combined to predict the probability of hemorrhage of digestive tract caused by antiplatelet drugs, with a predictive sensitivity of 0. 606, a specificity of 0. 900, a Yoden index of 0. 506, a threshold of 0. 616, and an area under the curve of 0. 809. CONCLUSIONS: The first symptom of hemorrhage of digestive tract caused by antiplatelet drugs is mostly black stool. Mild to moderate bleeding and moderate anemia can be observed. Age, history of hypertension, history of digestive tract diseases, Hp infection, Hp infection complicated with mucosal atrophy, abnormal Hb, abnormal Cr, type of drug use, course of treatment, and combination of PPI are related factors that affect hemorrhage of digestive tract caused by antiplatelet drugs. Clinical intervention should be actively targeted at bleeding factors, and joint evaluation of factors affecting hemorrhage of digestive tract caused by antiplatelet drugs has certain predictive value. [ABSTRACT FROM AUTHOR]

Antiplatelet drugs such as aspirin and clopidogrel are the cornerstones of the secondary prevention of coronary heart disease ( CHD), which can significantly improve treatment outcomes; however, long-term use increases the risk of bleeding and drug resistance. Recent clinical studies have shown that the combination of Chinese medicinals for promoting blood circulation and removing blood stasis with antiplatelet drugs has further reduced the disability rate and mortality of patients with CHD without increasing the risk of bleeding, but the evidence needs to be further strengthened for clinical application. Therefore, to achieve the secondary prevention of CHD, it is important to expand the clinical and mechanistic studies on the prevention and treatment of CHD with Chinese medicinals for promoting blood circulation and removing blood stasis combined with antiplatelet drugs according to the requirements of evidence-based medicine,objectively evaluating its efficacy and safety advantages, and exploring its biological mechanism. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Stroke is the property of Chinese Journal of Stroke Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Antiplatelet and anticoagulant therapy are required in the treatment of peripheral arterial disease (PAD) to prevent thrombosis and maintain vascular patency, and the selection of an appropriate antiplatelet and anticoagulant therapy strategy is essential to ensure efficacy and clinical prognosis. This paper summarizes and analyzes the antiplatelet and anticoagulant therapy regimens and clinical research results of PAD at home and abroad. New regimen of antiplatelet drugs combined with anticoagulant drugs in patients with PAD is significantly better than traditional antiplatelet or anticoagulant therapy alone, without increasing the risk of bleeding. The emerging antiplatelet combined with anticoagulant therapy (aspirin + rivaroxaban) is currently the safest and most effective treatment strategy, and patients can benefit the most, marking a new era of PAD treatment mode. [ABSTRACT FROM AUTHOR]

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To summarize the value of thromboelastogram (TEG) parameters in the treatment and prognosis evaluation of hypertensive intracerebral hemorrhage patients with oral antiplatelet drug. Methods The types of antiplatelet drug taken by hypertensive intracerebral hemorrhage patients admitted to Nanjing First Hospital and Nanjing Brain Hospital from January 2017 to December 2021 due to long-term oral antiplatelet before surgery and the results of TEG were analyzed retrospectively. According to the inhibitory rate of arachidonic acid (AA), patients were divided into inhibitory group and non-inhibitory group. The imaging HE signs, hematoma enlargement or postoperative rebleeding, number of surgical cases, operation time and neurological function recovery were compared between the inhibition group and the non-inhibition group, and statistical analysis was performed. Results A total of 67 patients with hypertensive intracerebral hemorrhage with TEG results were included, including 32 patients taking aspirin, 25 taking clopidogrel, and 10 taking combined aspirin and clopidogrel. According to the results of TEG, 39 cases belong to the AA inhibition group and 28 belong to the non-inhibition group. There were 13 cases of HE sign in inhibition group and 3 of HE sign in non-inhibition group. There was statistical difference between the two groups 19 patients (P=0.031). In the inhibition group, 35 patients underwent surgery. While in the non-inhibition group, underwent surgery. There was statistical difference between the two groups (P = 0.026). There were 5 cases of hematoma enlargement or postoperative rebleeding in the inhibition group, and no hematoma enlargement or postoperative rebleeding in the non-inhibition group, with statistical difference between the two groups (P = 0.037). The average operation time of the inhibition group was (3.3 ± 0.43) hours. The average duration of surgery in the uninhibited group was (3.9±0.40) hours. The GCS score at admission and following ADL score scale after 3 months in the non-inhibited group were better than those in the inhibited group. Conclusion For hypertensive intracerebral hemorrhage patients taking antiplatelet drugs, thrombolysis diagram shows a positive correlation between AA inhibition rate and hematoma enlargement and operation time, and a negatively correlated with the outcome of neurological dysfunction recovery, which can be used as an independent prognostic factor for patients with hypertensive intracerebral hemorrhage taking antiplatelet drugs. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To investigate the application of antiplatelet drugs on patients with cardiovascular disease during hospitalization in Tianjin, so as to provide references for standardizing rational drug application. METHODS: Inpatients in department of cardiovascular in 10 hospitals in Tianjin from 2017 to 2020 were set as subjects, Epidata software was used to conduct data input, SPSS 26. 0 was used for data collecting and analyzing. RESULTS: Totally 1 178 patients were involved, of which 499 patients(42. 4%) with angina pectoris, 158 patients(13. 4%) with acute myocardial infarction, 390 patients(33. 1%) with coronary heart disease,131 patients(11. 1%) with other types of diseases; the selection rate of antiplatelet drugs from high to low were respectively aspirin, clopidogrel, ticagrelor, tirofiban and cilostazol; the administration route of loading dose combination were mainly with aspirin and clopidogrel, but the loading dose application rate was low; the administration route of maintenance dose combination were mainly with aspirin and clopidogrel; there were differences in the characteristics of the medication behavior of different diseases, while there were also inconsistencies in characteristics of the medication behavior of same disease. CONCLUSIONS: There are differences in the medication behavior of inpatients with cardiovascular diseases in Tianjin in the drug selection, loading dose, maintenance dose and drug combination of antiplatelet drugs, the scientific and standardized treatment strategy still needs to be confirmed by large sample of real-world studies. [ABSTRACT FROM AUTHOR]

全球卒中的疾病负担沉重，抗血小板治疗是缺血性卒中二级预防的必要手段，然而东西 方人群的疾病特点存在差异，可能对抗血小板治疗的选择产生影响。本综述从卒中发病特点、患者复 发和出血风险差异以及抗血小板治疗反应多样性等多角度出发，探讨适合亚洲人群的缺血性卒中抗 血小板治疗方案。 Abstract: Stroke has become a global disease burden. Antiplatelet therapy is a necessary method for secondary prevention of ischemic stroke. However, there are differences between Easterners and Westerners on features of disease, which may lead to different antiplatelet therapy. Through the analysis of difference in disease characteristics, risk of recurrence and bleeding, and variability of platelet response, this review will explore the appropriate antiplatelet therapy for ischemic stroke patients in Asia.

Objective To analyze the safety of endovascular treatment with dual antiplatelet and heparin within 6 h and 24 h after external ventricular drainage(EVD) for aneurysmal subarachnoid hemorrhage(aSAH) combined with acute hydrocephalus. Methods The clinical data of 19 consecutive cases of (aSAH) were analyzed retrospectively. All patients were combined with acute hydrocephalus who underwent EVD first, endovascular treatment was performed within 24 hours after surgery, 300 mg clopidogrel and 300 mg aspirin were given by nasal feeding before anesthesia, and heparin was used intraoperatively. The time interval between EVD and the use of heparin was recorded and the risk of hemorrhage associated with EVD at different time intervals was analyzed. Results Of 19 patients, 13 were stent-assisted coiling, 2 were balloon assisted coil, 1 was double micro-catheter coiling and 3 were single micro-catheter coiling.Of 19 patients, 12 received endovascular treatment within 6 hours after EVD, and 7 received endovascular treatment within 6－24 hours after EVD. A small amount of puncture channel bleeding occurred in 2 cases underwent endovascular treatment within 6 hours after EVD, while no external ventricular drainage related bleeding occurred in the remaining 17 cases. During the operation, thrombosis of the central sulcus artery occurred in 1 patient, and tirofiban was used to make recanalization. Conclusions For patients with aSAH complicated with acute hydrocephalus, it is safe to apply dual antiplatelet and heparin in endovascular treatment of aneurysms within 24 hours after EVD. Endovascular treatment within 6 hours after EVD using dual antiplatelet and heparin is safe. It is safe and feasible to treat ruptured aneurysms in early stage after EVD. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Modern Laboratory Medicine is the property of Journal of Modern Laboratory Medicine Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)